MBX Biosciences, Inc. MBX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $75.23M+9.4% | $79.16M+37.9% | $74.62M+49.5% | $72.1M+70.7% | $68.77M— | ||
| $23.56M+86.5% | $18.9M+75.3% | $16.25M+68.3% | $14.46M+66.9% | $12.64M— | ||
| $98.79M+21.4% | $98.06M+43.8% | $90.87M+52.5% | $86.56M+70.0% | $81.41M— | ||
| -$98.79M-21.4% | -$98.06M-43.8% | -$90.87M-52.5% | -$86.56M-70.0% | -$81.41M— | ||
| -$86.64M-17.9% | -$87M-40.5% | -$80.5M-45.9% | -$77.02M-63.2% | -$73.47M-88.6% | ||
| -$2.16— | -$2.37— | —— | —— | —— | ||
| -$98.47M-21.5% | -$97.72M-43.9% | -$90.54M-52.7% | -$86.22M-70.3% | -$81.07M— | ||
| -$98.79M-21.4% | -$98.06M-43.8% | -$90.87M-52.5% | -$86.56M-70.0% | -$81.41M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is MBX Biosciences, Inc. profitable?
- MBX Biosciences, Inc. is not currently profitable: it reported a net loss of $86.6M over the trailing twelve months.
- What is MBX Biosciences, Inc.'s earnings per share?
- MBX Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-2.16.
- Where does MBX Biosciences, Inc.'s income statement data come from?
- Every line is extracted from MBX Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.